Peter Collins

1 month ago | ejog.org | Muhammad Saad |Muhammad Arshad |Baylor Scott |Peter Collins

KeywordsEndometriosisCardiovascular diseaseIschemic heart diseaseStrokeArrhythmiaWomen’s healthIntroductionCardiovascular disease (CVD) remains the leading global cause of death among women, accounting for approximately one-third of all deaths[1]. Notably, middle-aged women (45–64 years) are experiencing the most rapid relative increase in atherosclerotic cardiovascular disease (ASCVD) mortality, highlighting this demographic as a critical high-risk group requiring focused attention [1,2].

Dec 4, 2024 | blueline.ca | Peter Collins

Throughout my career, I have encountered officers whose lives have been affected by severe problem gambling, leading to separation, divorce, Police Act charges for stealing, and, in one case, suicide. Problem gambling (more recently referred to as a gambling disorder by the American Psychiatric Association) is now recognized as a public health concern.

Oct 25, 2024 | associationofanaesthetists-publications.onlinelibrary.wiley.com | Sarah Bell |Hazel Taylor |Philip Pallmann |Peter Collins

Fibrinogen is essential for haemostasis and can fall to critically low levels in acute haemorrhage [1]. The long turnaround time for laboratory Clauss fibrinogen has led to interest in point-of-care viscoelastic haemostatic assays to identify hypofibrinogenemia. The ROTEM® Delta and Sigma devices (Werfen, Warrington, UK) offer the FIBTEM assay to assess fibrinogen contribution to clot strength in whole blood.

Sep 1, 2024 | blueline.ca | Peter Collins

Although my role as an operational forensic psychiatrist with the police is primarily assisting as a criminal investigative psychiatrist, I have occasionally been asked to assess police officers who have engaged in boundary violations that victimize women. In medicine, distinct boundaries separate the relationship between a physician and patient. Other professions, like policing, have similar boundaries.

Jul 23, 2024 | onlinelibrary.wiley.com | Carolyn Webb |Peter Collins |Mevin A. Philip |Turja Chakraborty

Introduction Heart failure (HF) presents a considerable global public health concern, with a prevalence of an estimated 64.3 million cases worldwide.1 Due to improvements in treatments and survival after diagnosis, together with an ageing population, the prevalence of HF is likely to rise. Now more than ever, there is interest in finding new efficacious and affordable treatment alternatives for patients with HF.